<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004662</url>
  </required_header>
  <id_info>
    <org_study_id>199/11918</org_study_id>
    <secondary_id>NU-584</secondary_id>
    <nct_id>NCT00004662</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the safety and efficacy of synthetic dehydroepiandrosterone, GL701, in women with&#xD;
      active systemic lupus erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by participating&#xD;
      institution.&#xD;
&#xD;
      Patients are randomly assigned to daily oral dehydroepiandrosterone or placebo for 52 weeks.&#xD;
      Patients are evaluated every 13 weeks on study and return for a follow-up 6 weeks after&#xD;
      completion of therapy.&#xD;
&#xD;
      Concurrent therapy with estrogen replacement and stable doses of prednisone, azathioprine,&#xD;
      methotrexate (with folate supplementation), hydroxychloroquine, and nonsteroidal&#xD;
      anti-inflammatory drugs is allowed. Other investigational medications and immunosuppressants&#xD;
      are prohibited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dehydroepiandrosterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Systemic lupus erythematosus by 1982 American College of Rheumatology criteria Diagnosed&#xD;
        for at least 6 months&#xD;
&#xD;
        Systemic Lupus Activity Measure score at least 7 Points for erythrocyte sedimentation rate&#xD;
        excluded&#xD;
&#xD;
        SLEDAI score of greater than 2 at both screening and qualifying visits&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        No prior participation in any dehydroepiandrosterone (DHEA) study&#xD;
&#xD;
        No investigational agent within the longer of 30 days or 10 half-lives of the agent&#xD;
&#xD;
        Prednisone (or equivalent) dose 0 to 10 mg/day Unchanged for at least 6 weeks prior to&#xD;
        entry&#xD;
&#xD;
        At least 3 months since immunosuppressants other than azathioprine and methotrexate,&#xD;
        including:&#xD;
&#xD;
          -  DHEA&#xD;
&#xD;
          -  Adrenocorticotropin hormone&#xD;
&#xD;
          -  Androgens&#xD;
&#xD;
          -  Cyclophosphamide&#xD;
&#xD;
          -  Cyclosporine&#xD;
&#xD;
          -  Immune globulin&#xD;
&#xD;
        At least 6 weeks since change in azathioprine, methotrexate, or hydroxychloroquine&#xD;
&#xD;
        --Patient Characteristics-- Renal: No requirement for hemodialysis&#xD;
&#xD;
        Cardiovascular: No serious abnormality on electrocardiogram&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No hypersensitivity to DHEA or inactive ingredients in GL701 formulation, i.e.,&#xD;
             cornstarch, lactose, or magnesium stearate&#xD;
&#xD;
          -  No history of breast cancer or reproductive tract malignancy&#xD;
&#xD;
          -  Cervical carcinoma eligible if surgically cured, i.e., no evidence of disease for 5&#xD;
             years&#xD;
&#xD;
          -  No condition that would prevent compliance or follow-up, e.g.: Alcoholism Drug&#xD;
             addiction Acute withdrawal from chemical dependency&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  No pregnant or nursing women&#xD;
&#xD;
          -  Negative pregnancy test required of fertile women&#xD;
&#xD;
          -  Reliable contraception required of fertile women&#xD;
&#xD;
          -  No estrogen-containing oral contraceptives on study&#xD;
&#xD;
          -  At least 3 weeks since estrogen-containing oral contraceptives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosalind Ramsey-Goldman</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>arthritis &amp; connective tissue diseases</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

